Rounds. B-cell lymphoma with intermediate- to high-grade features and different immunophenotypic profiles involving separate anatomic sites with a good response to R-CHOP.

Autor: Lee RV, Green CA, Negrea OG, Dodson S, Farrell SK, Hewitt JE, Jago T, Ramsey CE, Cato T, Crawford E, Henley DC, Phelan MC, Potter NT

Publikováno v: Laboratory Medicine; Feb2009, Vol. 40 Issue 2, p79-86, 8p

Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer.

Autor: Singh H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Klempner SJ; Harvard Medical School, Boston, MA.; Massachusetts General Hospital Cancer Center, Boston, MA., Melnitchouk N; Harvard Medical School, Boston, MA.; Department of Surgery, Brigham and Women's Hospital, Boston, MA., Chander DP; Dana-Farber Cancer Institute at South Shore Hospital, Weymouth, MA., Negrea OG; Memorial Health University Medical Center, Savannah, GA., Patel AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Schlechter BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Rubinson DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Huffman BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Nambiar C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Remland J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Andrews E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Leahy ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Brais LK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Enzinger PC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Mamon HJ; Harvard Medical School, Boston, MA.; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA., Giannakis M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Meyerhardt JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Perez KJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Clark JW; Harvard Medical School, Boston, MA.; Massachusetts General Hospital Cancer Center, Boston, MA., Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2023 Jun; Vol. 7, pp. e2200572.

Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.

Autor: Liebman HA; Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA. liebman@usc.edu, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA, Goldenberg DM

Publikováno v: British journal of haematology [Br J Haematol] 2013 Sep; Vol. 162 (5), pp. 693-701. Date of Electronic Publication: 2013 Jul 06.